Journal article

Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology

Shalini S Rao, Larissa Lago, Irene Volitakis, Jay J Shukla, Gawain McColl, David I Finkelstein, Paul A Adlard

Neurotherapeutics | SPRINGER | Published : 2021

Abstract

The accumulation of neurofibrillary tangles (NFTs), which is composed of abnormally hyperphosphorylated tau aggregates, is the classic neuropathology associated with cognitive dysfunction in tauopathies such as Alzheimer's disease (AD). However, there is an emerging theory suggesting that dysregulation in cerebral iron may contribute to NFT formation. Iron is speculated to bind to tau and induce conformational changes of the protein, potentially leading to subsequent aggregation and cognitive decline. Deferiprone (DFP) is a clinically available iron chelator, which has demonstrated potential therapeutic advantages of chelating iron in neurodegenerative disorders, and is currently in clinical..

View full abstract

Grants

Funding Acknowledgements

The Florey Institute of Neuroscience and Mental Health acknowledge the strong support from the Victorian Government and, in particular, the funding from the Operational Infrastructure Support Grant. The authors would like to thank Blaine Roberts and the Neuroproteomics Facility (Florey) for the use of the SEC-ICP-MS equipment. SSR would also like to thank the Core Animal Services staff and other members of the Florey and the Melbourne Dementia Research Centre for their assistance throughout the project, and SSR was supported by a Parkinson's Victoria-Argyrou Family PhD Partner Scholarship.